Market Cap 30.86B
Revenue (ttm) 9.89B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 12.57
Forward PE 14.46
Profit Margin 13.07%
Debt to Equity Ratio 0.34
Volume 3,902,200
Avg Vol 1,241,118
Day's Range N/A - N/A
Shares Out 147.64M
Stochastic %K 9%
Beta 0.16
Analysts Strong Sell
Price Target $223.45

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
Pineapple1
Pineapple1 Jul. 14 at 8:24 PM
https://stocktwits.com/news-articles/markets/equity/biib-stock-on-track-for-worst-day-in-2-years-after-rbc-questions-if-alzheimer-s-drug-benefits-will-replicate-in-further-study/cZZR3T5R7qn $BIIB Have they shown brain volume maintenance? Specific bio-markers that determine which patients will benefit from treatment? What side effects? Is Tau really the cause of cognitive decline? Autophagy seems to be a better explanation.
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 7:12 PM
$BIIB same fate of AZN
0 · Reply
jewell69
jewell69 Jul. 14 at 6:57 PM
$BIIB re-entry 7/14 tuesday 2:55 pm edt 07/14/2026 Buy BIIB BIOGEN INC 48 $194.15 -$9,319.20 More 05/27/2026 Sell BIIB BIOGEN INC 10 $196.2218 $0.04 $1,962.18 More 05/19/2026 Buy BIIB BIOGEN INC 10 $191.94 -$1,919.40 More Total $0.04 -$9,276.42
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 14 at 6:38 PM
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study $BIIB $VTI $VOO https://stocktwits.com/news/equity/markets/biib-stock-on-track-for-worst-day-in-2-years-after-rbc-questions-if-alzheimer-s-drug-benefits-will-replicate-in-further-study/cZZR3T5R7qn
0 · Reply
ChrisMarketDiary
ChrisMarketDiary Jul. 14 at 6:37 PM
$BIIB Biogen fell after its Phase 2 Alzheimer's data missed the primary endpoint. The surprising part: • Low dose slowed cognitive decline by 26% • Strong reductions in tau biomarkers • Higher doses increased side effects without improving efficacy That's why the market sold the news. The data shows promise, but the unusual dose-response raises questions heading into Phase 3. Watching how $BIIB trades after the dust settles. Follow for more biotech catalysts and market insights.
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 6:01 PM
$BIIB AGX
0 · Reply
flychicken1991
flychicken1991 Jul. 14 at 5:47 PM
$BIIB Negative (92%): shares face direct downward pressure because the failed primary endpoint reduces the expected value assigned to diranersen and removes part of the upside investors had priced into Biogen's Alzheimer’s pipeline. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/352645fc515b03db?utm_source=stocktwits&utm_medium=story_url
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 3:51 PM
$BIIB sellogen and buy $ABBV or $AMGN
0 · Reply
ryphllps
ryphllps Jul. 14 at 3:28 PM
$BIIB talk about a real swinger
0 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 14 at 2:58 PM
$ANVS According to Biib drop Alzheimers phase 2 Data is worth 2Billion in market cap. Wonder how much phase 3 Alzheimers data is worth???? $BIIB
1 · Reply
Latest News on BIIB
Ionis says Biogen presents Phase 2 CELIA data at AAIC

2026-07-14T13:25:19.000Z - 16 hours ago

Ionis says Biogen presents Phase 2 CELIA data at AAIC

IONS


Biogen price target raised to $201 from $196 at Wedbush

2026-07-13T12:05:56.000Z - 1 day ago

Biogen price target raised to $201 from $196 at Wedbush


Biogen upgraded to Buy from Hold at Truist

2026-07-13T09:15:18.000Z - 1 day ago

Biogen upgraded to Buy from Hold at Truist


Biogen price target raised to $217 from $203 at BofA

2026-07-08T10:06:13.000Z - 6 days ago

Biogen price target raised to $217 from $203 at BofA


Biogen price target raised to $242 from $227 at RBC Capital

2026-07-07T11:26:14.000Z - 7 days ago

Biogen price target raised to $242 from $227 at RBC Capital


Biogen price target raised to $157 from $150 at HSBC

2026-07-06T14:25:54.000Z - 8 days ago

Biogen price target raised to $157 from $150 at HSBC


Old cancer drug may help restore fertility for certain women

Jul 1, 2026, 7:18 AM EDT - 13 days ago

Old cancer drug may help restore fertility for certain women


Biogen to acquire RayThera for $1 billion

Jun 17, 2026, 7:10 PM EDT - 27 days ago

Biogen to acquire RayThera for $1 billion


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 27 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


Biogen Transcript: AGM 2026

Jun 9, 2026, 9:00 AM EDT - 5 weeks ago

Biogen Transcript: AGM 2026


Biogen Completes Acquisition of Apellis Pharmaceuticals

May 14, 2026, 8:35 AM EDT - 2 months ago

Biogen Completes Acquisition of Apellis Pharmaceuticals


Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 7:03 AM EDT - 2 months ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal


Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Earnings Call Transcript: Q1 2026


Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Slides: Q1 2026


Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Earnings release: Q1 2026


Biogen Quarterly report: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Biogen Quarterly report: Q1 2026


Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 7:02 AM EDT - 2 months ago

Biogen Lowers 2026 Earnings Outlook


Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing


Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Biogen Proxy statement: Proxy filing


Why This Pharma Stock More Than Doubled Today

Mar 31, 2026, 9:41 AM EDT - 3 months ago

Why This Pharma Stock More Than Doubled Today

APLS


Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Transcript: M&A announcement


Biogen Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Press release: M&A announcement


Biogen Slides: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 3 months ago

Biogen Slides: M&A announcement


Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Mar 31, 2026, 7:44 AM EDT - 3 months ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS


Biogen to buy Apellis Pharmaceuticals for $5.6 billion

Mar 31, 2026, 7:05 AM EDT - 3 months ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS


Pineapple1
Pineapple1 Jul. 14 at 8:24 PM
https://stocktwits.com/news-articles/markets/equity/biib-stock-on-track-for-worst-day-in-2-years-after-rbc-questions-if-alzheimer-s-drug-benefits-will-replicate-in-further-study/cZZR3T5R7qn $BIIB Have they shown brain volume maintenance? Specific bio-markers that determine which patients will benefit from treatment? What side effects? Is Tau really the cause of cognitive decline? Autophagy seems to be a better explanation.
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 7:12 PM
$BIIB same fate of AZN
0 · Reply
jewell69
jewell69 Jul. 14 at 6:57 PM
$BIIB re-entry 7/14 tuesday 2:55 pm edt 07/14/2026 Buy BIIB BIOGEN INC 48 $194.15 -$9,319.20 More 05/27/2026 Sell BIIB BIOGEN INC 10 $196.2218 $0.04 $1,962.18 More 05/19/2026 Buy BIIB BIOGEN INC 10 $191.94 -$1,919.40 More Total $0.04 -$9,276.42
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 14 at 6:38 PM
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study $BIIB $VTI $VOO https://stocktwits.com/news/equity/markets/biib-stock-on-track-for-worst-day-in-2-years-after-rbc-questions-if-alzheimer-s-drug-benefits-will-replicate-in-further-study/cZZR3T5R7qn
0 · Reply
ChrisMarketDiary
ChrisMarketDiary Jul. 14 at 6:37 PM
$BIIB Biogen fell after its Phase 2 Alzheimer's data missed the primary endpoint. The surprising part: • Low dose slowed cognitive decline by 26% • Strong reductions in tau biomarkers • Higher doses increased side effects without improving efficacy That's why the market sold the news. The data shows promise, but the unusual dose-response raises questions heading into Phase 3. Watching how $BIIB trades after the dust settles. Follow for more biotech catalysts and market insights.
0 · Reply
Bazziggr
Bazziggr Jul. 14 at 6:01 PM
$BIIB AGX
0 · Reply
flychicken1991
flychicken1991 Jul. 14 at 5:47 PM
$BIIB Negative (92%): shares face direct downward pressure because the failed primary endpoint reduces the expected value assigned to diranersen and removes part of the upside investors had priced into Biogen's Alzheimer’s pipeline. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/352645fc515b03db?utm_source=stocktwits&utm_medium=story_url
0 · Reply
Options_Destroyer
Options_Destroyer Jul. 14 at 3:51 PM
$BIIB sellogen and buy $ABBV or $AMGN
0 · Reply
ryphllps
ryphllps Jul. 14 at 3:28 PM
$BIIB talk about a real swinger
0 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 14 at 2:58 PM
$ANVS According to Biib drop Alzheimers phase 2 Data is worth 2Billion in market cap. Wonder how much phase 3 Alzheimers data is worth???? $BIIB
1 · Reply
notreload_ai
notreload_ai Jul. 14 at 2:57 PM
$BIIB diranersen showed robust tau reductions (50-65%) and slowed cognitive decline by up to 26% in its Phase 2 CELIA trial. Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile. Mixed Phase 2 results still advance the competitive tau gene-silencing space including $VYGR, $ARWR, and $DNLI. https://notreload.xyz/xy/biogen-diranersen-phase-2-results-promising-tau-drug-misses-primary-endpoint/
1 · Reply
fitoto
fitoto Jul. 14 at 2:26 PM
$BIIB Why does it go down? Looks like a good P2 results.
0 · Reply
topstockalerts
topstockalerts Jul. 14 at 2:20 PM
Biogen unveiled Phase 2 CELIA trial results showing that its experimental Alzheimer's therapy diranersen delivered encouraging clinical benefits while significantly reducing tau pathology, supporting plans to advance the drug into Phase 3 development. Across all dose groups over 18 months, the antisense oligonucleotide lowered cerebrospinal fluid total tau by 50%-65% and reduced brain tau measured by PET imaging. The 60 mg dose produced the strongest clinical outcomes, slowing cognitive decline by 42% on ADAS-Cog13, 50% on MMSE, and 26% on CDR-SB. Although the trial did not meet its primary endpoint of demonstrating a dose-response effect on CDR-SB, Biogen said diranersen is the first anti-tau therapy to show reductions in both cerebrospinal fluid tau and brain tau pathology in a Phase 2 study. The treatment was generally well tolerated, with mostly mild to moderate adverse events, and more than 90% of eligible participants enrolled in the open-label extension. $BIIB
0 · Reply
dogDazeSummer
dogDazeSummer Jul. 14 at 1:57 PM
$IFRX Welcome Fidelity Sector Fund. The first real mutual fund for our German baby in a long time. Now w funding risk removed in “shoe in for AAV” (given Amgen sketchiness. EMA / FDA clearly seek retribution). And the first major Biotech *mutual fund* takes a 3.2m share starter. Follow the leaders. This Fidelity fund holds about 114 positions Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund 3.2M shares Inflarx. May 31, 2026 4.42% 6,392,142 26 year old fund FY July, +22% YTD; +77% TTM; 10% over 10 years. 159 Holdings Inflarx is now just 1 of 6 international holdings. Obviously a special situation and wisely bought on pullbacks 5 Star Mormingside Fund in all categories Profile: Eirene Kontopoulos Since 07/14/2018 B.S., Haverford College, 2002 PhD, Harvard University - Harvard Medical School, 2007 Top Holdings: $ABBV $GILD $BIIB $ALNY https://institutional.fidelity.com/app/funds-and-products/116/fidelity-advisor-biotechnology-fund-class-i-fbtix.html
0 · Reply
biotech
biotech Jul. 14 at 1:36 PM
$SGMO TAU .... no ARIA as with Amyloid shown at $BIIB
0 · Reply
biotech
biotech Jul. 14 at 1:30 PM
$SGMO $SGMO TAU is hot - re $BIIB $IONS Alzheimers news this morning tau-directed therapy to demonstrate robust reductions in both CSF total tau, with mean reductions of 50–65%, and brain tau pathology, across all studied doses in a Phase 2 study https://investors.biogen.com/news-releases/news-release-details/biogen-presents-phase-2-celia-data-aaic-demonstrating-meaningful
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 14 at 1:16 PM
$BIIB (+1.9% pre) Biogen presents Phase 2 data on Alzheimer's drug diranersen at AAIC https://ooc.bz/l/107742
0 · Reply
Quantumup
Quantumup Jul. 14 at 12:10 PM
Goldman Sachs y'day🏁 $STOK and said -- We initiate coverage of Stoke Therapeutics (STOK) with a Buy rating and a 12-month price target of $44 (85%-weighted DCF value of $43, 15%-weighted M&A value of $49; M&A rank of 2). $BIIB $PRAX DRUG HLUBF HLBBF HRMY IONS OVID UCBJY JAZZ Here's what else Goldman Sachs had to say: https://x.com/Quantumup1/status/2077002438909784198?s=20
0 · Reply
Merlintrader
Merlintrader Jul. 14 at 12:02 PM
$BIIB Biotech Radar July 14, 2026: Biogen, AstraZeneca, GSK and Evotec — $BIIB, $AZN, $GSK, $EVO https://www.merlintrader.com/biotech-radar-july14-2026/
0 · Reply
GoforProMIS
GoforProMIS Jul. 14 at 10:25 AM
$PMN with best in class results at the Alzheimer’s Association International Conference (AAIC) as the world’s largest and most important professional conference dedicated to Alzheimer’s and dementia research. Key figures: Around 12,000 participants from across the globe attended AAIC 2025. Of these, over 8,000 attended in person, while more than 3,000 joined online. Participants came from 139 countries. Participants include: Neurologists Alzheimer’s researchers Representatives from universities Pharmaceutical companies $LLY , $BIIB , $RHHVF , $ESALY , etc. Investors and biotech analysts FDA and regulatory representatives Clinical trial investigators. Get ready for amazing day, week and months to come 🚀 https://www.promisneurosciences.com/investors/news-events/press-releases/detail/269/promis-neurosciences-reports-first-human-evidence-of
0 · Reply
CNBCTV18
CNBCTV18 Jul. 14 at 5:13 AM
🧠 All eyes are on $BIIB today as the drugmaker is set to unveil phase-2 trial data for its experimental Alzheimer's treatment at the Alzheimer's Association International Conference in London. https://www.cnbctv18.com/business/companies/watch-out-for-new-drug-data-for-alzheimers-treatment-today-19944746.htm
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Jul. 14 at 4:47 AM
$BIIB - Day Move: +4.96% $MDGL - Day Move: +4.16% #XLE ETF: +2–3% | #WTI Crude: +8.78% to $77.68 | Biggest Oil Move Since 2020 #BLK - Day Move: +1.61% MAGS ETF (Roundhill Magnificent 7 ETF) — The Defensive Tech Play Holding Green $MRK - Day Move: +1.22% $AAPL $TSM https://truthsandnews.com/markets/top-gainer-stocks-today-july-13-2026-energy-biotech-movers
0 · Reply